Piribo, the online destination for business intelligence for the biotech and pharmaceutical industry, has added a new report analysing the drug delivery partnering agreements in pharma and biotech.
“Drug Delivery Partnering Agreements In Pharma & Biotech” provides an understanding and access to the drug delivery partnering agreements entered into by the worlds leading healthcare companies.
The 408 page report shows that the majority of deals are development stage whereby the licensee obtains a right or an option right to license the licensors drug delivery technology or drug delivery-enabled product candidates.
Authors of the report highlight that an understanding of the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms.
Furthermore, the report contains over 800 links to online copies of actual drug delivery contract documents as submitted to the Securities Exchange Commission by companies and their partners.
These contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.
The report is divided into chapters, one for example, provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of drug delivery contract documents available in the public domain.
“Drug Delivery Partnering Agreements In Pharma & Biotech” is available from Piribo. For more information go to:
http://www.piribo.com/
Piribo product ID: CTP00167
